Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
New York-based Formation Bio originally launched in 2016 under the name TrialSpark as a service provider that helped companies more rapidly enroll clinical trials. Its prior investors Sequoia, Thrive, Emerson Collective and Lachy Groom participated in the recent series D round along with new investors, including SV Angel Growth and FPV Ventures.
The round’s proceeds will support ongoing buildout of Formation’s AI capabilities as well as acquisition and licensing of clinical-stage drug...
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
